{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:17:37Z","timestamp":1761895057035},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"22","license":[{"start":{"date-parts":[[2010,3,22]],"date-time":"2010-03-22T00:00:00Z","timestamp":1269216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,3,22]],"date-time":"2010-03-22T00:00:00Z","timestamp":1269216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2010,6,3]]},"DOI":"10.1038\/onc.2010.81","type":"journal-article","created":{"date-parts":[[2010,3,22]],"date-time":"2010-03-22T11:15:47Z","timestamp":1269256547000},"page":"3276-3286","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Bortezomib decreases Rb phosphorylation and induces caspase-dependent apoptosis in Imatinib-sensitive and -resistant Bcr-Abl1-expressing cells"],"prefix":"10.1038","volume":"29","author":[{"given":"M P","family":"Albero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J M","family":"Vaquer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E J","family":"Andreu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J J","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Franch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Ivorra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Poch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X","family":"Agirre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Prosper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"P\u00e9rez-Roger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,3,22]]},"reference":[{"key":"BFonc201081_CR1","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0093-7754(01)90034-X","volume":"28","author":"J Adams","year":"2001","unstructured":"Adams J . (2001). Proteasome inhibition in cancer: development of PS-341. Semin Oncol 28: 613\u2013619.","journal-title":"Semin Oncol"},{"key":"BFonc201081_CR2","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1158\/0008-5472.CAN-04-1357","volume":"65","author":"EJ Andreu","year":"2005","unstructured":"Andreu EJ, Lledo E, Poch E, Ivorra C, Albero MP, Martinez-Climent JA et al. (2005). BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Cancer Res 65: 3264\u20133272.","journal-title":"Cancer Res"},{"key":"BFonc201081_CR3","doi-asserted-by":"publisher","first-page":"4841","DOI":"10.1038\/sj.emboj.7601899","volume":"26","author":"B Barre","year":"2007","unstructured":"Barre B, Perkins ND . (2007). A cell cycle regulatory network controlling NF-kappaB subunit activity and function. EMBO J 26: 4841\u20134855.","journal-title":"EMBO J"},{"key":"BFonc201081_CR4","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1093\/jnci\/djj309","volume":"98","author":"C Brignole","year":"2006","unstructured":"Brignole C, Marimpietri D, Pastorino F, Nico B, Di Paolo D, Cioni M et al. (2006). Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst 98: 1142\u20131157.","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 1","key":"BFonc201081_CR5","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/1471-2091-9-S1-S1","volume":"9","author":"D Chauhan","year":"2008","unstructured":"Chauhan D, Bianchi G, Anderson KC . (2008). Targeting the UPS as therapy in multiple myeloma. BMC Biochem 9 (Suppl 1): S1.","journal-title":"BMC Biochem"},{"key":"BFonc201081_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P . (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27\u201355.","journal-title":"Adv Enzyme Regul"},{"key":"BFonc201081_CR7","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.exphem.2008.11.004","volume":"37","author":"LJ Crawford","year":"2009","unstructured":"Crawford LJ, Windrum P, Magill L, Melo JV, McCallum L, McMullin MF et al. (2009). Proteasome proteolytic profile is linked to Bcr-Abl expression. Exp Hematol 37: 357\u2013366.","journal-title":"Exp Hematol"},{"key":"BFonc201081_CR8","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1182\/blood-2003-12-4121","volume":"104","author":"Y Dai","year":"2004","unstructured":"Dai Y, Rahmani M, Pei XY, Dent P, Grant S . (2004). Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr\/Abl-dependent and -independent mechanisms. Blood 104: 509\u2013518.","journal-title":"Blood"},{"key":"BFonc201081_CR9","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.leukres.2006.01.005","volume":"30","author":"G Dasmahapatra","year":"2006","unstructured":"Dasmahapatra G, Nguyen TK, Dent P, Grant S . (2006). Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr\/Abl. Leuk Res 30: 1263\u20131272.","journal-title":"Leuk Res"},{"key":"BFonc201081_CR10","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","volume":"112","author":"BJ Druker","year":"2008","unstructured":"Druker BJ . (2008). Translation of the Philadelphia chromosome into therapy for CML. Blood 112: 4808\u20134817.","journal-title":"Blood"},{"key":"BFonc201081_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.leukres.2007.05.023","volume":"32","author":"S Galimberti","year":"2008","unstructured":"Galimberti S, Canestraro M, Pacini S, Fazzi R, Orciuolo E, Trombi L et al. (2008). PS-341 (Bortezomib) inhibits proliferation and induces apoptosis of megakaryoblastic MO7-e cells. Leuk Res 32: 103\u2013112.","journal-title":"Leuk Res"},{"key":"BFonc201081_CR12","first-page":"853","volume":"88","author":"S Gatto","year":"2003","unstructured":"Gatto S, Scappini B, Pham L, Onida F, Milella M, Ball G et al. (2003). The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr\/Abl-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica 88: 853\u2013863.","journal-title":"Haematologica"},{"key":"BFonc201081_CR13","doi-asserted-by":"publisher","first-page":"6082","DOI":"10.1128\/MCB.02202-05","volume":"26","author":"IJ Griswold","year":"2006","unstructured":"Griswold IJ, Macpartlin M, Bumm T, Goss VL, O'Hare T, Lee KA et al. (2006). Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol 26: 6082\u20136093.","journal-title":"Mol Cell Biol"},{"issue":"11","key":"BFonc201081_CR14","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1182\/blood-2008-06-164582","volume":"115","author":"N. B. Heaney","year":"2010","unstructured":"Heaney NB, Pellicano F, Zhang B, Crawford L, Chu S, Kazmi SM et al. (2010). Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD\/SCID repopulating cells. Blood (e-pub ahead of print 12 January 2010; doi:10.1182\/blood-2008-06-164582).","journal-title":"Blood"},{"key":"BFonc201081_CR15","doi-asserted-by":"publisher","first-page":"6201","DOI":"10.1038\/sj.onc.1203022","volume":"18","author":"M Heusch","year":"1999","unstructured":"Heusch M, Lin L, Geleziunas R, Greene WC . (1999). The generation of nfkb2 p52: mechanism and efficiency. Oncogene 18: 6201\u20136208.","journal-title":"Oncogene"},{"key":"BFonc201081_CR16","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.1002\/j.1460-2075.1996.tb01089.x","volume":"15","author":"RU Janicke","year":"1996","unstructured":"Janicke RU, Walker PA, Lin XY, Porter AG . (1996). Specific cleavage of the retinoblastoma protein by an ICE-like protease in apoptosis. EMBO J 15: 6969\u20136978.","journal-title":"EMBO J"},{"key":"BFonc201081_CR17","doi-asserted-by":"publisher","first-page":"7840","DOI":"10.1158\/0008-5472.CAN-06-2033","volume":"66","author":"CA Joazeiro","year":"2006","unstructured":"Joazeiro CA, Anderson KC, Hunter T . (2006). Proteasome inhibitor drugs on the rise. Cancer Res 66: 7840\u20137842.","journal-title":"Cancer Res"},{"key":"BFonc201081_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10637-006-9000-0","volume":"25","author":"Y Kano","year":"2007","unstructured":"Kano Y, Akutsu M, Tsunoda S, Izumi T, Kobayashi H, Mano H et al. (2007). Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia\/lymphoma agents against human leukemia\/lymphoma cell lines. Invest New Drugs 25: 31\u201340.","journal-title":"Invest New Drugs"},{"key":"BFonc201081_CR19","doi-asserted-by":"publisher","first-page":"5210","DOI":"10.1038\/sj.onc.1209612","volume":"25","author":"L Khidr","year":"2006","unstructured":"Khidr L, Chen PL . (2006). RB, the conductor that orchestrates life, death and differentiation. Oncogene 25: 5210\u20135219.","journal-title":"Oncogene"},{"key":"BFonc201081_CR20","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1101\/gad.321004","volume":"18","author":"U Kossatz","year":"2004","unstructured":"Kossatz U, Dietrich N, Zender L, Buer J, Manns MP, Malek NP . (2004). Skp2-dependent degradation of p27kip1 is essential for cell cycle progression. Genes Dev 18: 2602\u20132607.","journal-title":"Genes Dev"},{"key":"BFonc201081_CR21","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1158\/1541-7786.MCR-08-0108","volume":"6","author":"S Markovina","year":"2008","unstructured":"Markovina S, Callander NS, O'Connor SL, Kim J, Werndli JE, Raschko M et al. (2008). Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. Mol Cancer Res 6: 1356\u20131364.","journal-title":"Mol Cancer Res"},{"key":"BFonc201081_CR22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S0092-8674(03)01080-8","volume":"116","author":"AW Murray","year":"2004","unstructured":"Murray AW . (2004). Recycling the cell cycle: cyclins revisited. Cell 116: 221\u2013234.","journal-title":"Cell"},{"key":"BFonc201081_CR23","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/S1470-2045(08)70304-8","volume":"9","author":"EM Ocio","year":"2008","unstructured":"Ocio EM, Mateos MV, Maiso P, Pandiella A, San-Miguel JF . (2008). New drugs in multiple myeloma: mechanisms of action and phase I\/II clinical findings. Lancet Oncol 9: 1157\u20131165.","journal-title":"Lancet Oncol"},{"key":"BFonc201081_CR24","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1182\/blood-2005-05-2091","volume":"107","author":"P Perez-Galan","year":"2006","unstructured":"Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D . (2006). The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 107: 257\u2013264.","journal-title":"Blood"},{"key":"BFonc201081_CR25","doi-asserted-by":"publisher","first-page":"5310","DOI":"10.1093\/emboj\/18.19.5310","volume":"18","author":"I Perez-Roger","year":"1999","unstructured":"Perez-Roger I, Kim SH, Griffiths B, Sewing A, Land H . (1999). Cyclins D1 and D2 mediate myc-induced proliferation via sequestration of p27(Kip1) and p21(Cip1). EMBO J 18: 5310\u20135320.","journal-title":"EMBO J"},{"key":"BFonc201081_CR26","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.yexcr.2006.11.006","volume":"313","author":"E Poch","year":"2007","unstructured":"Poch E, Minambres R, Mocholi E, Ivorra C, Perez-Arago A, Guerri C et al. (2007). RhoE interferes with Rb inactivation and regulates the proliferation and survival of the U87 human glioblastoma cell line. Exp Cell Res 313: 719\u2013731.","journal-title":"Exp Cell Res"},{"key":"BFonc201081_CR27","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S1097-2765(02)00697-4","volume":"10","author":"JL Pomerantz","year":"2002","unstructured":"Pomerantz JL, Baltimore D . (2002). Two pathways to NF-kappaB. Mol Cell 10: 693\u2013695.","journal-title":"Mol Cell"},{"key":"BFonc201081_CR28","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1634\/theoncologist.2007-0170","volume":"13","author":"P Ramirez","year":"2008","unstructured":"Ramirez P, DiPersio JF . (2008). Therapy options in imatinib failures. Oncologist 13: 424\u2013434.","journal-title":"Oncologist"},{"key":"BFonc201081_CR29","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3324\/haematol.10782","volume":"92","author":"J Roman-Gomez","year":"2007","unstructured":"Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo JA, Navarro G, San Jose-Eneriz E et al. (2007). Epigenetic regulation of human cancer\/testis antigen gene, HAGE, in chronic myeloid leukemia. Haematologica 92: 153\u2013162.","journal-title":"Haematologica"},{"key":"BFonc201081_CR30","doi-asserted-by":"publisher","first-page":"5942","DOI":"10.1158\/1078-0432.CCR-07-0536","volume":"13","author":"A Sartore-Bianchi","year":"2007","unstructured":"Sartore-Bianchi A, Gasparri F, Galvani A, Nici L, Darnowski JW, Barbone D et al. (2007). Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res 13: 5942\u20135951.","journal-title":"Clin Cancer Res"},{"key":"BFonc201081_CR31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3109\/10428199309047862","volume":"11","author":"CL Sawyers","year":"1993","unstructured":"Sawyers CL . (1993). The role of myc in transformation by BCR-ABL. Leuk Lymphoma 11: 45\u201346.","journal-title":"Leuk Lymphoma"},{"key":"BFonc201081_CR32","doi-asserted-by":"publisher","first-page":"7389","DOI":"10.1038\/sj.onc.1206942","volume":"22","author":"NP Shah","year":"2003","unstructured":"Shah NP, Sawyers CL . (2003). Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 22: 7389\u20137395.","journal-title":"Oncogene"},{"key":"BFonc201081_CR33","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1101\/gad.1256504","volume":"18","author":"CJ Sherr","year":"2004","unstructured":"Sherr CJ, Roberts JM . (2004). Living with or without cyclins and cyclin-dependent kinases. Genes Dev 18: 2699\u20132711.","journal-title":"Genes Dev"},{"key":"BFonc201081_CR34","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/j.1365-2141.2007.06504.x","volume":"136","author":"C Stapnes","year":"2007","unstructured":"Stapnes C, Doskeland AP, Hatfield K, Ersvaer E, Ryningen A, Lorens JB et al. (2007). The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. Br J Haematol 136: 814\u2013828.","journal-title":"Br J Haematol"},{"key":"BFonc201081_CR35","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1158\/0008-5472.CAN-06-3254","volume":"67","author":"SJ Strauss","year":"2007","unstructured":"Strauss SJ, Higginbottom K, Juliger S, Maharaj L, Allen P, Schenkein D et al. (2007). The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. Cancer Res 67: 2783\u20132790.","journal-title":"Cancer Res"},{"key":"BFonc201081_CR36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1749-0774.2005.tb00054.x","volume":"18","author":"PN Van","year":"2005","unstructured":"Van PN, Xinh PT, Kano Y, Tokunaga K, Sato Y . (2005). Establishment and characterization of a novel Philadelphia-chromosome positive chronic myeloid leukemia cell line, TCC-S, expressing P210 and P190 Bcr\/Abl transcripts but missing normal ABL gene. Hum Cell 18: 25\u201333.","journal-title":"Hum Cell"},{"key":"BFonc201081_CR37","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1365-2141.2006.06170.x","volume":"134","author":"J Vink","year":"2006","unstructured":"Vink J, Cloos J, Kaspers GJ . (2006). Proteasome inhibition as novel treatment strategy in leukaemia. Br J Haematol 134: 253\u2013262.","journal-title":"Br J Haematol"},{"key":"BFonc201081_CR38","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1080\/10428190801942378","volume":"49","author":"AH Wei","year":"2008","unstructured":"Wei AH, Roberts AW . (2008). Bortezomib: putting mantle cell lymphoma on death row. Leuk Lymphoma 49: 657\u2013658.","journal-title":"Leuk Lymphoma"},{"key":"BFonc201081_CR39","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1038\/sj.leu.2404735","volume":"21","author":"H Yan","year":"2007","unstructured":"Yan H, Wang YC, Li D, Wang Y, Liu W, Wu YL et al. (2007). Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta. Leukemia 21: 1488\u20131495.","journal-title":"Leukemia"},{"key":"BFonc201081_CR40","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1476-4598-7-40","volume":"7","author":"DT Yang","year":"2008","unstructured":"Yang DT, Young KH, Kahl BS, Markovina S, Miyamoto S . (2008). Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. Mol Cancer 7: 40.","journal-title":"Mol Cancer"},{"key":"BFonc201081_CR41","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1182\/blood-2003-03-0737","volume":"102","author":"C Yu","year":"2003","unstructured":"Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S . (2003). The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr\/Abl+ cells sensitive and resistant to STI571. Blood 102: 3765\u20133774.","journal-title":"Blood"},{"key":"BFonc201081_CR42","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.leukres.2007.05.024","volume":"32","author":"X Zhao","year":"2008","unstructured":"Zhao X, Qiu W, Kung J, Peng X, Yegappan M, Yen-Lieberman B et al. (2008). Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies. Leuk Res 32: 275\u2013285.","journal-title":"Leuk Res"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc201081.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc201081","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc201081.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T17:17:08Z","timestamp":1647883028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc201081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,22]]},"references-count":42,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2010,6,3]]}},"alternative-id":["BFonc201081"],"URL":"https:\/\/doi.org\/10.1038\/onc.2010.81","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,22]]},"assertion":[{"value":"10 April 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2010","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}